XOMA Company Description
XOMA doesn't want to toil in anonymity. Instead, the company pairs with larger drug firms to develop and market its products, primarily monoclonal antibodies. XOMA receives royalties from biotech giant Genentech on two FDA-approved products: psoriasis treatment Raptiva, which it co-developed with Genentech; and Lucentis, a treatment for age-related macular degeneration that Genentech developed with technology licensed from XOMA. The company is developing some candidates, including potential diabetes treatment XOMA 052, in-house; and it has additional collaborative agreements with Novartis (to develop cancer therapies) and the National Institutes of Health (to find treatments for bioterror threat botulinum).
View the Comprehensive Company Description for XOMA
The Company Description provides a historical perspective of XOMA's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of XOMA's evolution in the marketplace.
